Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: Stock Watcher who wrote (5010)	3/26/1999 11:11:00 AM
From: Dave Gore	Read Replies (1) \| Respond to of 52051

One to watch: CELN Unique cancer & protate treatment with MIT, Duke University, and Massachusetts General Hospital, and Oxford University in England CELN* QUICK INFO FOR NEW SHAREHOLDERS. Has an exclusive license from MIT to provide targeted heat, non-invasive breast tumor cancer solutions. This technology has been around for over 2 decades but only now can they generate high concentrated heat to the tumor cell without burning outside tissue and more importantly , to kill the cancel cells. PROGRESS: Phase One trials to begin on humans soon and whole process is fairly short, as their technology is NOT a drug, so does not have the lengthy testing period. Equipment, as opposed to drugs, only has 2 phases. The human results should come back within months. ** Even more timely is their OUTPATIENT treatment for Prostate problems. It will involve a related heat treatment to expand the opening so no serious operation is required. While the breast cancer treatment could be a life-saver and great news since a mastectomy could be avoided, so would a simple outpatient treatment to 50% of all men who eventually sometime in their life will experience minor or severe problems in the prostrate area. PROGRESS: Phase I under way on humans for the prostate BPH treatment. Will be marketed outside the U.S. soon, and pre-clinical application in the U.S. soon as well they hope. The BPH treatment is ahead of the breast tumor, but both should have significant news shortly. REMEMBER….with equipment technology, there is not the lengthy PHASE 1,2, and 3. The complete cycle time is much much shorter than drugs. Clinical evaluations of the first generation system, which has an Investigational Device Exemption (IDE) from the Food and Drug Administration (FDA), are underway at the Montefiore Medical Center in Bronx, NY to demonstrate clinical efficacy in humans. Once the clinicals are completed, Celsion intends to bring its BPH treatment system to market abroad and apply for FDA Premarket Approval (PMA) for commercialization in the U.S. "Our current BPH system is positioned to notably expand the $9 billion worldwide market for BPH treatment by encouraging more men to seek treatment, especially those with moderate symptoms," stated CELN President and CEO Spencer Volk. "We expect the current clinical studies to confirm the 'walk-in be treated, walk-out with total relief' nature of our out-patient BPH system. Once the accuracy of the new temperature sensing device is verified in animals, we will include that capability in our BPH treatment system." ABOUT CELSION In addition to its BPH treatment system, under an FDA IDE Celsion is preparing to conduct clinicals of its breast cancer treatment system to demonstrate that focused heat alone safely and effectively ablates tumors. Celsion's research is concentrated on designing focused heat systems to treat additional cancers. Celsion Corporation is a research and development company dedicated to commercializing medical treatment systems for cancer and BPH using focused heat delivered by patented microwave technology. Clinicals and further development of the Company's treatment systems are being conducted by leading institutions such as the Massachusetts Institute of Technology, Massachusetts General Hospital, Montefiore Medical Center, and Duke University. OTHER NEWS: COLUMBIA, Md.--(BW HealthWire)--Dec. 23, 1998--Celsion Corporation (OTC BB: CELN) today announced that the U.S. District Court of Maryland found in favor of the Company regarding a lawsuit filed by Eastwell Management Services, Ltd. for $250,000 In a related decision the U.S. District Court of Maryland also found in favor of Celsion regarding its countersuit, concluding that Celsion is entitled to $100,000 from Eastwell Management Services which breached the original contract between the two parties. Celsion reported that it will pursue all legally possible avenues to collect the $100,000 from Eastwell Management Services. Celsion Corporation is a research and development company dedicated to commercializing medical treatment systems for cancer and benign prostatic hyperplasia (BPH) using focused heat delivered by several patented microwave technologies. Clinicals and further development of Celsion's systems are being conducted by leading institutions such as the Massachusetts Institute of Technology, Massachusetts General Hospital, Montefiore Medical Center, and Duke University in the United States, and Hammersmith Hospital and Oxford University in England.